Biogen (BIIB) Announces CFO Retirement
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/12/2026
- US stock futures gain ahead of July inflation data
- Oil prices rise after ship attacks, US-Iran talks deadlock
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- Lumentum Holdings (LITE) Tops Q4 EPS by 28c, Beats on Revenue; Offers Q1 Guidance
- Aurora Cannabis rejects Curaleaf's unsolicited $4-per-share takeover bid
- AbCellera Biologics (ABCL) PT Raised to $30 at Truist on 'best-in-class potential'
- Wall Street ends down as US-Iran peace optimism fades
- Comscore plans restructuring with $20M-$25M in cost cuts
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
Biogen (BIIB) PT Raised to $315 at Piper Sandler
October 30, 2024 4:54 PM EDTPiper Sandler analyst Christopher Raymond raised the price target on Biogen (NASDAQ: BIIB) to $315.00 (from $307.00) while maintaining a Overweight rating.
The analyst comments "Remain OW rated on BIIB shares after a solid Q324 beat/FY24 guidance raise. While some may quibble... More
Goldman Sachs Reiterates Buy Rating on Biogen (BIIB)
October 30, 2024 4:37 PM EDTGoldman Sachs analyst Salveen Richter reiterated a Buy rating and $290.00 price target on Biogen (NASDAQ: BIIB).
The analyst comments "BIIB posted in-line 3Q revenue, inclusive of Leqembi's beat and Skyclarys' miss, and higher EPS per cost-savings. Leqembi's launch remains affected by infrastructure/logistical challenges, where we continue to expect a gradual, albeit progressing, uptake curve and are... More
